NxClinical 4.1 is a unique software solution for integration of copy number, sequence variants, and allelic changes obtained from microarray and NGS technologies. NxClinical 4.1 allows combined analysis and interpretation of all genomic variants on a single, platform agnostic system.
BioDiscovery announced today an agreement with Be Creative Lab in Beijing, China to be the exclusive reseller and distributor of BioDiscovery products in China.
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay.
GENALICE and BioDiscovery announce a co-marketing partnership to offer their products together as a turn-key end-to-end solution for the use of next-generation sequencing (NGS) data to interpret genomes.
NxClinical 3.0 will be launched during the ASHG 2016 Meeting, October 18-21 in Vancouver, BC, Canada
Ambry Genetics selects BioDiscovery’s NxClinical software for analysis, management, and reporting of copy number events in its clinical genomics workflow.
Illumina Selects BioDiscovery’s NxClinical Software for Data Visualization, Management and Interpretation for its CytoSeq ™ assay, an NGS-based Solution for Detection of CNVs, AOH, and SNVs
CombiMatrix is now using BioDiscovery’s NxClinical software for analysis, management, and interpretation of copy number events in its clinical workflow.
Recognized leader in research and education, and one of the top pediatric providers in the Midwest recently started using NxClinical.
A genomics services provider for clinical trials, testing, and research will now be working with BioDiscovery in a co-marketing partnership.